Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Yamaguchi
Masaki
M
Munemoto
Saori
S
Kasada
Atsuo
A
Murata
Ryoichi
R
Ueda
Mikio
M
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D055728:Primary Myelofibrosis / Q000150:complications*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib